Jazz Pharmaceuticals plc (JAZZ)
Fair ValueFundamental
70
मूल्य
$231.52
मार्केट कैप
$15.03B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$4.60B
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$941M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$1.30B
कुल इक्विटी
$4.32B
कुल देनदारियाँ
$7.34B
Current Ratio
1.78
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$257.79
वर्तमान मूल्य
$231.52
Margin of Safety
+10.2%
Fair Value सीमा
$167.57 - $348.02
इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
15.83
ROE
-8.2%
P/B Ratio
3.13
P/FCF
9.44
Gross Margin
-
ROIC
8.0%
लाभप्रदता Radar
मूल्य सृजन (प्रतिस्पर्धी बढ़त)
ROIC
8.0%
WACC
6.2%
ROIC − WACC
+1.8 pp
ROIC पूंजी की लागत से अधिक है — कंपनी शेयरधारकों के लिए मूल्य सृजित कर रही है।
Fundamental विश्लेषण मानदंड
पास (17)
- Price CAGR 7.98%
- ROIC 8.0%
- P/FCF 9.44
- Debt/Equity ratio
- Operating Margin 19.5%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Return on Tangible Assets
- ROE 21.4%
- Revenue Growth 5Y 12.5%
- Analyst Consensus 92% Buy
- Earnings Surprise avg 15.3%
- Earnings Quality (OCF/NI) 1.77
- Share Dilution -5.8%
- Net Margin Trend 20.4% vs -9.9%
- Piotroski F-Score 5/9
फेल (5)
- EPS shows upward trend
- P/B Ratio 3.13
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
अनुपलब्ध (5)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
- Debt/EBITDA
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक
Earnings गुणवत्ता
उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
संस्थागत होल्डिंग
इस कंपनी के लिए कोई संस्थागत घोषणा उपलब्ध नहीं है।
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Bruce C. Cozadd | Co-Founder & Chairman | 61 |
| Ms. Renee D. Gala | President, CEO & Director | 53 |
| Mr. Philip L. Johnson | Executive VP & CFO | 61 |
| Ms. Neena M. Patil J.D. | Executive VP & Chief Legal Officer | 50 |
| Dr. Robert Iannone M.D. | Executive VP, Chief Medical Officer and Global Head of Research & Development | 58 |
| Ms. Samantha Pearce | Executive VP & Chief Commercial Officer | 59 |
| Ms. Patricia Carr | Senior VP & Chief Accounting Officer | 54 |
| Mr. John D. Bluth | Head of Investor Relations | 52 |
| Ms. Heidi Manna | Executive VP & Chief People Officer | 54 |
| Dr. Jed Black M.D. | Senior Vice President of Sleep & CNS Medicine | - |
Audit जोखिम
8
बोर्ड जोखिम
4
मुआवजा जोखिम
5
शेयरधारक अधिकार जोखिम
3
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
दस्तावेज़
- दस्तावेज़ देखें
वार्षिक रिपोर्ट (10-K)
कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।
दाखिल तिथि: 2026-02-24
- दस्तावेज़ देखें
तिमाही रिपोर्ट (10-Q)
पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।
दाखिल तिथि: 2026-08-03
- दस्तावेज़ देखें
विशेष रिपोर्ट (8-K)
किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।
दाखिल तिथि: 2026-09-23
via SEC EDGAR
आय का इतिहास
via SEC EDGAR
Latest News
Recent headlines for JAZZ, sourced from Markets Gazette.
- 6/17/2026POSITIVEJazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
Jazz Pharmaceuticals has entered into a strategic collaboration with AbCellera to discover and develop novel cancer therapies. This partnership aims to leverage AbCellera's AI-powered antibody discovery platform to identify potential drug candidates for challenging oncology targets. Despite a recent setback in a Zepzelca trial, this move signals Jazz's commitment to strengthening its oncology pipeline. Analysts remain optimistic, maintaining positive price targets, suggesting that this collaboration could be a significant catalyst for future growth and value creation for shareholders.
via Markets Gazette